Structure Therapeutics Inc.’s American depositary receipts jumped more than 90% premarket on Friday after the company announced positive results from an...
Structure Therapeutics Inc.’s American depositary receipts GPCR, +4.96% jumped more than 90% premarket on Friday after the company announced positive results from an early-stage trial of a weight-loss treatment and a $300 million private placement. The company’s oral GLP-1 receptor agonist, GSBR-1290, resulted in placebo-adjusted weight loss of up to 5% in healthy patients with obesity or overweight after 28 days, the company said in a release.
Structure said it continues to plan the launch of a phase 2b study of the treatment in type 2 diabetes next year. The company on Friday also announced a $300 million private placement financing, with “participation from a number of large healthcare dedicated institutional and mutual fund investors.” The proceeds will go toward accelerating GSBR-1290 development as well as other programs from the company’s oral incretin franchise, Structure CEO Raymond Stevens said in a statement.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Martin Scorsese Refusing 1 Studio Demand Saved His $300 Million Best Picture Winner From DisasterMartin Scorsese answers to no studio.
Read more »
House approves bill providing $300 million in aid to UkraineThe House voted to provide $300 million in aid to Ukraine, passing the measure as a stand-alone bill after it was stripped from the annual defense spending bill in an effort by GOP leaders to appease hard-line conservatives and secure their support to advance the must-pass legislation when it came…
Read more »
Soleno Therapeutics Stock Dives After Its Meteoric Rise on Positive Study ResultsThe biotechnology company had announced positive study results for its DCCR tablets on Tuesday.
Read more »
Amgen discloses more than $400 million stake in recent IPO Neumora TherapeuticsAn Amgen disclosure of a large stake in Neumora Therapeutics indicated the value of its investment in the biotech, which recently went public, has tripled.
Read more »
FDA Panel Rejects Brainstorm Cell Therapeutics ALS TreatmentBy Liz Essley Whyte A U.S. Food and Drug Administration advisory committee voted against a treatment from BrainStorm Cell Therapeutics for amyotrophic...
Read more »
Brainstorm Cell Therapeutics shares fall more than 50% after FDA advisors vote down ALS treatmentBrainStorm Cell Therapeutics Inc. shares fell 56% premarket on Thursday after advisors to the U.S. Food and Drug Administration on Wednesday gave a...
Read more »